ENDURANCE Analysis Shows Blood-Pressure Management Reduces Stroke Risk In VAD Patients
Executive Summary
A post-hoc analysis of the combined data from the ENDURANCE and ENDURANCE Supplemental trials shows a relationship between severely disabling stroke and one-year mortality in patients treated with Medtronic’s HeartWare HVAD as well as other left-ventricular assist devices (LVAD), including Abbott’s HeartMate II, and that blood-pressure control significantly reduces the risk of stroke events from six-months to two-years post-implant.
You may also be interested in...
Cost-Effectiveness Studies Support Medtronic's HeartWare HVAD
A cost-effectiveness analysis of the LATERAL trial shows patients treated with Medtronic’s HeartWare HVAD through the less-invasive thoracotomy procedure incurred lower hospitalization and medical supply costs than patients implanted with a ventricular assist device through the traditional sternotomy approach. Another new analysis shows HeartWare HVAD is more cost-effective than ventricular assist devices of the past.
US FDA Approves Medtronic's HVAD For Destination Therapy
The expanded labeling gives Medtronic's HVAD, acquired when it bought HeartWare last summer, the same indication as Abbott's HeartMate II ventricular assist device.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.